During President Claudia Sheinbaum’s press conference this Thursday, the government announced more than 21 billion pesos in private investments for Mexico’s pharmaceutical sector as part of the so-called “Plan México.” The projects focus on manufacturing, clinical research, biotechnology, and the domestic production of medicines and medical supplies.
At the presentation held at the National Palace, Health Secretary David Kershenobich stated that the investments represent an important step toward strengthening Mexico’s industrial and pharmaceutical capacity.
“What will be announced today totals 21 billion pesos, but beyond the figure itself, it reflects the possibility of industrial development in the country and the ability to produce medicines domestically,” he said.
President Sheinbaum explained that pharmaceutical development is one of the strategic sectors her administration is promoting.
“One of the sectors we have been working on to encourage private investment in Mexico is the pharmaceutical industry,” she said.
“These are more than 21 billion pesos directed toward medicine production in Mexico, also linked to clinical research. As you know, the objective of Plan México is to produce more in Mexico of what we consume in Mexico, while also allowing us to export to other countries—not only to the United States, but also to diversify exports. Strengthening the pharmaceutical industry is extremely important. We appreciate the confidence in Mexico and our continued work for the benefit of all Mexicans,” she stated during the morning press conference known as “Las mañaneras del pueblo.”
Representatives from eight pharmaceutical companies explained that Mexico has the infrastructure, industrial capacity, and specialized talent needed to establish itself as a regional pharmaceutical hub.
Investment Announcements by Company
Abbott
CEO Edgar Romero announced an investment of 3.5 billion pesos, which is expected to create 1,200 jobs by 2030. The funds will support a new 20,000-square-meter facility in Santiago de Querétaro to expand the production of medical devices used in diagnosing and treating heart rhythm disorders.
Bristol Myers Squibb
CEO Oswaldo Bernal detailed an investment of 1 billion pesos that will create 380 direct jobs and 65 indirect jobs nationwide. The project aims to strengthen Mexico’s healthcare sovereignty through clinical research and local manufacturing of innovative therapies, ensuring better access to medicines.
Grupo Neolpharma
Director Luz Astrea Ocampo Gutiérrez announced a 750 million peso investment to build three plants capable of producing 2,300 tons of pharmaceutical raw materials annually in Toluca. The project will create 250 direct jobs and 900 indirect jobs.
Opella
CEO Luis Soares said the company will invest 2.3 billion pesos to expand and modernize its plant in Ocoyoacac, including a new production line for Enterogermina®, a digestive health medicine. The project aims to position Mexico as a regional pharmaceutical export platform for Latin America and will generate 50 direct jobs and 450 indirect jobs.
Laboratorios Kener
Federico Prince of Vazol Farma announced an investment of 5.36 billion pesos. Of that amount:
- 550 million pesos will expand the plant in Toluca,
- 1.35 billion pesos will support a Plasma Derivatives Plant in partnership with the Mexican government,
- 3.46 billion pesos will fund a biotechnology plant in collaboration with a multinational company.
The project will create 220 direct jobs and 550 indirect jobs. Prince added that this investment complements the 5.18 billion pesos announced in July 2025, bringing the total to 10.54 billion pesos.
Liomont
Biotechnology and Vaccines Director Sergio Valentinotti announced a 4 billion peso investment for:
- a new oral solids plant,
- expansion of biotechnology injectables and vaccine production in Ocoyoacac,
- increased bio-pharmaceutical and vaccine production,
- construction of an mRNA synthesis and encapsulation plant in Mexico City.
The project will create 370 direct jobs and 400 indirect jobs.
Sanofi
Corporate Affairs Director Paola Martorelli announced the construction of a new insulin production plant in Mexico for first-generation, second-generation, and rapid insulin. The investment exceeds 2 billion pesos and aims to provide full patient coverage.
Sanofi already operates a vaccine antigen plant in Ocoyoacac, generating nearly 900 direct jobs and more than 1,500 indirect jobs. The company produces over 150 million medicines and vaccines in Mexico and is investing an additional 655 million pesos in clinical studies as part of Plan México.
Bayer
Pharma Bayer México Director Daniel Landero reported 33% progress on a previously announced 3 billion peso investment from 2025, equivalent to 1 billion pesos already underway.
Additionally, Bayer announced a further 150 million peso investment to conduct 10 clinical studies in public and private institutions throughout Mexico. The company stated that these studies will improve Mexican patients’ access to innovation, strengthen the country’s healthcare infrastructure, and support sustainable industrial development.
Source: razon
